Jasper Therapeutics

Jasper Therapeutics Acquires Kira Pharmaceuticals, Expanding Immune Drug Pipeline and Securing $132M Lifeline

Jasper Therapeutics has acquired Kira Pharmaceuticals in an all-stock deal, securing a $132 million private offering to fund operations through H2 2028. This merger provides Jasper a critical lifeline, diversifying its pipeline with Kira's promising complement system inhibitors, KP-104 and KP-701, for rare immune and kidney diseases. This strategic move aims to revitalize Jasper's market position after prior setbacks, impacting competitive dynamics in PNH and IgA nephropathy.